Objective of this non-interventional study (NIS) is to collect data on the use of Grassmuno® in routine clinical practice.

At the physician's discretion and based on the current Summary of Product Characteristics (SmPC), study participation may be offered to patients who

• are male and female patients
• are 18 years of age or older
• treated in accordance with the SmPC of Grassmuno® for IgE-mediated moderate to severe allergic rhinitis and/or rhinoconjunctivitis (without asthma or with well-controlled asthma) triggered by grass pollen.
• Patients will only be enrolled in the study after the treatment decision has been made

Exclusion Criteria:

At the physician's discretion, the study should not be offered to the following patients:

• Patients who are not sufficiently proficient in or do not adequately understand the German language, as this would prevent adequate comprehension of study-relevant documents.
• In addition, patients should not be included if any of the contraindications listed in the current Summary of Product Characteristics (SmPC) are present.

Adult patients for whom a pre-seasonal subcutaneous allergen immunotherapy (AIT) with Grassmuno® for the treatment of IgE-mediated moderate to severe allergic rhinitis and/or rhinoconjunctivitis, without asthma or with well-controlled asthma elicicited by grass pollen is indicated.